Download the Investor Presentation & Receive Updates
Invest in a Pharmaceutical Cannabinoid Leader
Cardiol Therapeutics (TSX: CRDL) is a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer.
Agreements with Noramco and Dalton Pharma provide access to cannabinoid pharmaceuticals.
Cannabinoid drug candidates for the treatment of heart failure and Glioblastoma Multiforme.
Nanotechnology research aims to enhance the delivery of cannabinoids for heart failure.
Team is experienced in the research and commercialization of novel therapeutics.
Copyright © 2018 All Rights Reserved.
Sign Up to Learn More